Innovative Cellular Therapeutics, a Maryland-Shanghai biotech, presented data from its ongoing clinical trial and preclinical studies of its lead candidate, ICTCAR014, a combination of anti-CD19 CAR-T cells with a dominant negative PD1 molecule. In preclinical tests, these “armored” CAR-T cells show enhanced ability to kill tumors and more “memory-like” phenotypes compared to conventional CAR-T cells, the company says. In a China trial, two patients treated with ICTCAR014 for refractory diffuse large B-cell lymphoma (DLBCL) experienced a significant decrease in tumor mass.
Source: China Biotoday
